Capsule formulation of pirfenidone and pharmaceutically...

Details Capsule formulation of pirfenidone and pharmaceutically... Capsule formulation of pirfenidone and pharmaceutically...

2011-08-02

2011-08-02

Wax, Robert A (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Capsules

C514S345000, C424S451000, C424S489000

Reexamination Certificate

active

07988994

ABSTRACT:
A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient. Further provided are methods of treating fibrotic conditions and other cytokine-mediated disorders by administering pirfenidone capsules of such formulation to a patient in need.

REFERENCES:
patent: 3974281 (1976-08-01), Gadekar
patent: 5310562 (1994-05-01), Margolin
patent: 5518729 (1996-05-01), Margolin
patent: 5591766 (1997-01-01), Bang et al.
patent: 5716632 (1998-02-01), Margolin
patent: 6090822 (2000-07-01), Margolin
patent: 6300349 (2001-10-01), Margolin
patent: 2004/0048902 (2004-03-01), Kiyonaka et al.
patent: 2007/0054842 (2007-03-01), Blatt et al.
patent: 0383591 (1990-08-01), None
patent: 0458861 (1991-12-01), None
patent: 1138329 (2001-10-01), None
patent: 1356816 (2003-10-01), None
patent: WO-94/26249 (1994-11-01), None
patent: WO-97/10712 (1997-03-01), None
patent: WO-2004/019758A-2 (2004-03-01), None
patent: WO-2004/019863 (2004-03-01), None
patent: WO-2004/103296 (2004-12-01), None
patent: WO-2005/016241 (2005-02-01), None
patent: WO-2005/040758 (2005-05-01), None
patent: WO-2005/047256 (2005-05-01), None
Cain et al., Inhabition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone.Int. J. Immunopharmacol.20: 685-95 (1998).
Martinet et al., Exaggerated spontaneous release of platelet-derived growth factor by alveolar macrophages from patients with idiopathic pulmonary fibrosis.N. Engl. J. Med.317: 202-9 (1987).
Nagai et al., Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis,Intern. Med.41: 1118-23 (2002).
Schmidt et al., Bioavailability of pirfenidone capsules following oral administration (human volunteers) (60-244-73). Affiliated Medical Research, Inc. Princeton, New Jersey (1974).
Striker et al., Mesangial cell turnover: effect of heparin and peptide growth factor.Lab Invest.64: 446-56 (1991).
Van Barneveld et al., Natural course of bleomycin-induced pneumonitis . A follow-up study.Am. Rev. Respir Dis.135: 48-51 (1987).
Zhang et al., Pirfenidone reduces firbonectin synthesis by cultured human retinal pigment epithelial cells.Aust. N Z J. Ophthalmol.26: S74-6 (1998).
Combined PCT Search Report and Written Opinion, PCT/US2006/037057, Apr. 23, 2004.
International Preliminary Report on Patentability, PCT/US2006/037057, Apr. 23, 2004.
Report on Deliberation Results, Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau Ministry of Health, Labour and Welfare, Glaspia Tablets 200 mg (Sep. 16, 2008); http://www.pmda.go.jp/english/service/pdf/Pirespa-Pirfenidone.pdf.
Georgian Search Report, Georgian Patent Application No. 10558/01 (Jun. 15, 2009).
Singapore Written Opinion (issued by the Danish Patent Office), Singaporean Patent Application No. 200801941-6 (Apr. 24, 2009).
Gahl et al., “Effect of Pirfenidone on the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome,” Molecular Genetics and Metabolism 76: 234-42 (2002).
Azuma et al., “Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis,” Am J. Respir. Crit. Care Med. 171: 1040-47 (2005).
Notari, Biopharmaceutics and Clinical Pharmacokinetics: An Introduction, Marcel Dekker, Inc., New York and Basel, pp. 134-159 (4th ed. 1986).
InterMune, Dissolution Profile Comparison Study Report for Pirfenidone Capsules (Unpublished), Archival date Aug. 1, 2008.
Shionogi & Co., Ltd., Pirespe® Tablet 200 mg Pirfenidone Tablet, Package Insert (Version 1, Oct. 2008) and English-language translation thereof.
International Preliminary Report on Patentability for counterpart International Application No. PCT/US2006/037057 (Mar. 26, 2008).
International Search Report and Written Opinion for counterpart International Application No. PCT/US2006/037057 (Apr. 23, 2007).
U.S. Official Action, U.S. Appl. No. 12/426,182 (Sep. 16, 2009).
U.S. Official Action, U.S. Appl. No. 12/426,182 (Nov. 8, 2009).
U.S. Official Action, U.S. Appl. No. 12/426,182 (Apr. 8, 2010).

Affiliated with

Also associated with

Rating

Capsule formulation of pirfenidone and pharmaceutically... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Capsule formulation of pirfenidone and pharmaceutically..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Capsule formulation of pirfenidone and pharmaceutically... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2755331